Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma

Cobertura de los medios

• Nombre	Cabometyx® in combination with nivolumab shows durable survival benefits at over three-years' follow-up in first-line advanced renal cell carcinoma
  Nombre/canal del medio de comunicación	Hugin - English
  País/Territorio	Estados Unidos
  Fecha	13/02/23
  Personas	Mauricio Burotto